Literature DB >> 9663809

Studies with iontophoretic administration of drugs to human dermal vessels in vivo: cholinergic vasodilatation is mediated by dilator prostanoids rather than nitric oxide.

J P Noon1, B R Walker, M F Hand, D J Webb.   

Abstract

AIMS: Impaired function of the vascular endothelium has been well documented in hypertension and hypercholesterolaemia. However, the 'gold standard' method for assessing endothelial function, using intra-arterial drug infusion, is invasive and has only been applied in the forearm and coronary circulations in vivo. The aim of the present study was to establish the non-invasive technique of transdermal drug iontophoresis to assess endothelial function in human dermal vessels in vivo.
METHODS: In healthy male volunteers, we delivered acetylcholine (ACh) and sodium nitroprusside (SNP) to dermal vessels of the forearm using iontophoresis, and measured vasodilatation using laser Doppler fluximetry. Drugs were diluted in a methylcellulose gel vehicle which did not induce vasodilatation. To assess the contribution of nitric oxide and vasoactive prostanoids to cholinergic dilatation, the procedure was repeated during brachial artery infusion of the nitric oxide synthase inhibitor, L-N(G)-monomethyl-arginine (L-NMMA) and after intravenous administration of the cyclooxygenase inhibitor, aspirin. As a control for the vasoconstrictor effect of L-NMMA, which was measured by venous occlusion plethysmography, iontophoresis was repeated during brachial artery infusion of noradrenaline.
RESULTS: Flux increased in response to iontophoresis of ACh (from 45 +/- 9 to 499 +/- 80 units; P < 0.0001) and SNP (from 32 +/- 11 to 607 +/- 82 units; P < 0.0001). Brachial artery infusions of L-NMMA or noradrenaline caused reductions in forearm blood flow (by 43 +/- 2% and 44 +/- 2%, respectively) but did not inhibit vasodilatation in response to iontophoresis of ACh or SNP. In contrast, aspirin inhibited the response to iontophoresis of ACh (from 473 +/- 81 to 222 +/- 43 units; P < 0.0001) but did not affect the response to SNP (from 348 +/- 59 to 355 +/- 58).
CONCLUSIONS: We conclude that in healthy subjects, in contrast to the forearm circulation, dermal vasodilatation in response to iontophoresis of ACh is mediated predominately by a dilator prostanoid rather than by nitric oxide generation. Furthermore, the non-invasive technique of iontophoresis could complement existing invasive tests of endothelial function in future clinical studies.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9663809      PMCID: PMC1873656          DOI: 10.1046/j.1365-2125.1998.00718.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  25 in total

1.  An investigation into variability in microvascular skin blood flow and the responses to transdermal delivery of acetylcholine at different sites in the forearm and hand.

Authors:  J M Gardner-Medwin; J Y Taylor; I A Macdonald; R J Powell
Journal:  Br J Clin Pharmacol       Date:  1997-04       Impact factor: 4.335

2.  Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension.

Authors:  J A Panza; P R Casino; C M Kilcoyne; A A Quyyumi
Journal:  Circulation       Date:  1993-05       Impact factor: 29.690

3.  Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension.

Authors:  L Linder; W Kiowski; F R Bühler; T F Lüscher
Journal:  Circulation       Date:  1990-06       Impact factor: 29.690

4.  Interaction among ET-1, endothelium-derived nitric oxide, and prostacyclin in pulmonary arteries and veins.

Authors:  T M Zellers; J McCormick; Y Wu
Journal:  Am J Physiol       Date:  1994-07

5.  Effect of local intra-arterial NG-monomethyl-L-arginine in patients with hypertension: the nitric oxide dilator mechanism appears abnormal.

Authors:  A Calver; J Collier; S Moncada; P Vallance
Journal:  J Hypertens       Date:  1992-09       Impact factor: 4.844

6.  Glucocorticoids and blood pressure: a role for the cortisol/cortisone shuttle in the control of vascular tone in man.

Authors:  B R Walker; A A Connacher; D J Webb; C R Edwards
Journal:  Clin Sci (Lond)       Date:  1992-08       Impact factor: 6.124

7.  Preserved endothelium-dependent vasodilatation in patients with essential hypertension.

Authors:  J R Cockcroft; P J Chowienczyk; N Benjamin; J M Ritter
Journal:  N Engl J Med       Date:  1994-04-14       Impact factor: 91.245

8.  Hypertension and left ventricular hypertrophy are associated with impaired endothelium-mediated relaxation in human coronary resistance vessels.

Authors:  C B Treasure; J L Klein; J A Vita; S V Manoukian; G H Renwick; A P Selwyn; P Ganz; R W Alexander
Journal:  Circulation       Date:  1993-01       Impact factor: 29.690

9.  Impaired endothelium-dependent vasodilation of forearm resistance vessels in hypercholesterolaemia.

Authors:  P J Chowienczyk; G F Watts; J R Cockcroft; J M Ritter
Journal:  Lancet       Date:  1992-12-12       Impact factor: 79.321

10.  Vasodilation to acetylcholine in primary and secondary forms of human hypertension.

Authors:  S Taddei; A Virdis; P Mattei; A Salvetti
Journal:  Hypertension       Date:  1993-06       Impact factor: 10.190

View more
  18 in total

1.  Influence of compression pressure from the hand access device on hand microcirculation during hand-assisted laparoscopic surgery.

Authors:  S Manasnayakorn; F Khan; R A Levison; A Cuschieri; G B Hanna
Journal:  Surg Endosc       Date:  2008-10-15       Impact factor: 4.584

2.  Cutaneous blood flow during intradermal NO administration in young and older adults: roles for calcium-activated potassium channels and cyclooxygenase?

Authors:  Naoto Fujii; Robert D Meade; Christopher T Minson; Vienna E Brunt; Pierre Boulay; Ronald J Sigal; Glen P Kenny
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2016-04-06       Impact factor: 3.619

3.  Vascular responses of the extremities to transdermal application of vasoactive agents in Caucasian and African descent individuals.

Authors:  Matthew J Maley; James R House; Michael J Tipton; Clare M Eglin
Journal:  Eur J Appl Physiol       Date:  2015-04-04       Impact factor: 3.078

4.  Mechanisms of acetylcholine-mediated vasodilatation in young and aged human skin.

Authors:  Lacy A Holowatz; Caitlin S Thompson; Christopher T Minson; W Larry Kenney
Journal:  J Physiol       Date:  2005-01-20       Impact factor: 5.182

5.  Acute hyperhomocysteinaemia affects pulse pressure but not microvascular vasodilator function.

Authors:  K R Davis; H Pearson; S Moat; J R Bonham; R Donnelly
Journal:  Br J Clin Pharmacol       Date:  2001-09       Impact factor: 4.335

6.  Endothelial-derived hyperpolarization contributes to acetylcholine-mediated vasodilation in human skin in a dose-dependent manner.

Authors:  Vienna E Brunt; Naoto Fujii; Christopher T Minson
Journal:  J Appl Physiol (1985)       Date:  2015-09-17

7.  Cyclooxygenase inhibition does not alter methacholine-induced sweating.

Authors:  Naoto Fujii; Ryan McGinn; Gabrielle Paull; Jill M Stapleton; Robert D Meade; Glen P Kenny
Journal:  J Appl Physiol (1985)       Date:  2014-09-11

8.  The effect of nitric oxide synthase and cyclooxygenase inhibition on cutaneous microvascular reactivity.

Authors:  Helena Lenasi; Martin Strucl
Journal:  Eur J Appl Physiol       Date:  2008-05-31       Impact factor: 3.078

9.  Impaired microvascular function in normal children: effects of adiposity and poor glucose handling.

Authors:  Faisel Khan; Fiona C Green; J Stewart Forsyth; Stephen A Greene; Andrew D Morris; Jill J F Belch
Journal:  J Physiol       Date:  2003-06-24       Impact factor: 5.182

10.  Diffuse endothelial dysfunction is common to ANCA associated systemic vasculitis and polyarteritis nodosa.

Authors:  A D Filer; J M Gardner-Medwin; J Thambyrajah; K Raza; D M Carruthers; R J Stevens; L Liu; S E Lowe; J N Townend; P A Bacon
Journal:  Ann Rheum Dis       Date:  2003-02       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.